A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1–12. doi: 10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• Andersen YMF, Wu JJ, Thyssen JP, et al. Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis. J Am Acad Dermatol. 2019;81(6):1283–1291. doi: 10.1016/j.jaad.2019.04.033.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Khalid U, Gislason GH, et al. Impact of depression on risk of myocardial infarction, stroke and cardiovascular death in patients with psoriasis: a danish nationwide study. Acta Derm Venereol. 2016;96(2):218–221. doi: 10.2340/00015555-2218.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerback C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi: 10.1016/S0140-6736(21)00184-7.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057.
   PubMed Web of Science ®Google Scholar
• Reynolds KA, Pithadia DJ, Lee EB, et al. Safety and effectiveness of anti-Tumor necrosis Factor-Alpha biosimilar agents in the treatment of psoriasis. Am J Clin Dermatol. 2020;21(4):483–491. doi: 10.1007/s40257-020-00507-1.
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Galan-Gutierrez M. Biosimilars in psoriasis: what should your positioning be? Expert Opin Biol Ther. 2021;21(1):81–86. doi: 10.1080/14712598.2020.1798924.
   PubMed Web of Science ®Google Scholar
• Barker J, Girolomoni G, Egeberg A, et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat. 2020;31(8):794–800. doi: 10.1080/09546634.2019.1610553.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502. doi: 10.1111/bjd.15756.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839.
   PubMedGoogle Scholar
• Hesselvig JH, Egeberg A, Loft ND, et al. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3):335–339. doi: 10.2340/00015555-2833.
   PubMed Web of Science ®Google Scholar
• Silva MF, Fortes MR, Miot LD, et al. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013;88(5):760–763. doi: 10.1590/abd1806-4841.20132052.
   PubMed Web of Science ®Google Scholar
• Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:10–16. doi: 10.1111/j.1468-3083.2009.03562.x.
   PubMed Web of Science ®Google Scholar
• Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and psoriasis area and severity index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369–375. doi: 10.1016/j.jaad.2011.01.022.
   PubMed Web of Science ®Google Scholar
• NICE Evidence Reviews Collection. Evidence review for interventions to support effective shared decision making: shared decision making: evidence review B. London: national Institute for Health and Care Excellence (NICE) Copyright © NICE 2021. 2021.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Polesie S, Seyed-Alinaghi F, Egeberg A. A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with psoriasis and biological agents. PROSPERO 2021 CRD42021286077 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021286077.
   Google Scholar
• Bramer WM, Giustini D, de Jonge GB, et al. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–243. doi: 10.3163/1536-5050.104.3.014.
   PubMed Web of Science ®Google Scholar
• Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials: a requirement of the international committee of medical journal editors. Lancet. 2017;389(10086):e12–e14. doi: 10.1016/S0140-6736(17)31282-5.
   PubMed Web of Science ®Google Scholar
• Almutairi N, Eassa B. Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature. Postepy Dermatol Alergol. 2021;38(2):281–288. doi: 10.5114/ada.2019.91496.
   PubMed Web of Science ®Google Scholar
• AlMutairi N, Eassa BI. A randomized controlled ixekizumab Vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis. Expert Opin Biol Ther. 2021;21(2):297–298. doi: 10.1080/14712598.2021.1843629.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–1157. doi: 10.1136/ard.2004.032268.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310. doi: 10.1111/j.1346-8138.2009.00748.x.
   PubMed Web of Science ®Google Scholar
• Atalay S, van den Reek J, den Broeder AA, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2020;156(4):393–400. doi: 10.1001/jamadermatol.2019.4897.
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561. doi: 10.1016/S0140-6736(14)62113-9.
   PubMed Web of Science ®Google Scholar
• Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–674. doi: 10.1016/j.jaad.2017.05.033.
   PubMed Web of Science ®Google Scholar
• Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67(1):86–92. doi: 10.1016/j.jaad.2011.07.034.
   PubMed Web of Science ®Google Scholar
• Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-Week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571–579. doi: 10.1007/s13555-018-0265-y.
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71(4):541–548. doi: 10.1136/ard.2011.152223.
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165(5):1109–1117. doi: 10.1111/j.1365-2133.2011.10615.x.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–1408. doi: 10.1111/j.1468-3083.2011.03984.x.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022;33(4):2085–2093. doi: 10.1080/09546634.2021.1914812.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lacour JP, Fowler JF, Jr., et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631. doi: 10.1111/bjd.16890.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658. doi: 10.1001/jamadermatol.2020.0723.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358. doi: 10.1111/bjd.18851.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi: 10.1016/j.jaad.2016.11.041.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493. doi: 10.1111/bjd.13348.
   PubMed Web of Science ®Google Scholar
• Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89–95. doi: 10.1111/jdv.13746.
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020;133(22):2665–2673. doi: 10.1097/CM9.0000000000001163.
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31(1):107–113. doi: 10.1111/jdv.13768.
   PubMed Web of Science ®Google Scholar
• Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29(2):210–214. doi: 10.1007/s10875-008-9233-0.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842–1847. doi: 10.1016/s0140-6736(00)04954-0.
   PubMed Web of Science ®Google Scholar
• de Vries AC, Thio HB, de Kort WJ, et al. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the psoriasis infliximab vs. Etanercept comparison evaluation (PIECE) study. Br J Dermatol. 2017;176(3):624–633. doi: 10.1111/bjd.14867.
   PubMed Web of Science ®Google Scholar
• Dubertret L, Sterry W, Bos JD, et al. CLinical experience acquired with the efalizumab (raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155(1):170–181. doi: 10.1111/j.1365-2133.2006.07344.x.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(1):90–99 e91. doi: 10.1016/j.jaad.2017.08.029.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Reznichenko N, Pulka G, et al. Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, Double-Blind, randomised, parallel group, active control, phase III study. BioDrugs, 2021;35(6):735–748. doi: 10.1007/s40259-021-00502-w.
   PubMed Web of Science ®Google Scholar
• Ferris LK, Ott E, Jiang J, et al. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2020;31(2):152–159. doi: 10.1080/09546634.2019.1587145.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. 2011;164(6):1383–1386. doi: 10.1111/j.1365-2133.2011.10358.x.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345–1349. doi: 10.1111/j.1365-2133.2008.08564.x.
   PubMed Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001. doi: 10.1111/bcp.13185.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Suarez-Farinas M, Wang AC, et al. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial. JAMA Dermatol. 2015;151(8):837–846. doi: 10.1001/jamadermatol.2015.0452.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136–144. doi: 10.1056/NEJMoa1501646.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. doi: 10.1016/S0140-6736(21)00126-4.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304–314. doi: 10.1038/jid.2011.304.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. doi: 10.1016/j.jaad.2006.05.027.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290(23):3073–3080. doi: 10.1001/jama.290.23.3073.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi: 10.1016/S0140-6736(18)31713-6.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80. doi: 10.1016/j.jaad.2016.07.058.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Blauvelt A, Thaci D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314 e306. doi: 10.1016/j.jaad.2018.04.012.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6):829–835. doi: 10.1067/mjd.2003.307.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542. doi: 10.1016/j.jaad.2004.02.021.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–657. doi: 10.1111/j.1365-2133.2012.11015.x.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):652–660. doi: 10.1111/j.1365-2133.2011.10418.x.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–1632; discussion 1632. doi: 10.1001/archderm.139.12.1627.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Merola JF, Reich K, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124–1134. doi: 10.1111/bjd.20413.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi: 10.1016/S0140-6736(15)60125-8.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128. doi: 10.1056/NEJMoa0810652.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–938. doi: 10.1111/bjd.15152.
   PubMed Web of Science ®Google Scholar
• Harris KM, Smilek DE, Byron M, et al. Effect of costimulatory blockade with abatacept after ustekinumab withdrawal in patients with moderate to severe plaque psoriasis: the PAUSE randomized clinical trial. JAMA Dermatol. 2021;157(11):1306–1315. doi: 10.1001/jamadermatol.2021.3492.
   PubMed Web of Science ®Google Scholar
• Hercogova J, Papp KA, Chyrok V, et al. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316–326. doi: 10.1111/bjd.18220.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–252. doi: 10.1111/j.1346-8138.2011.01347.x.
   PubMed Web of Science ®Google Scholar
• Karakawa M, Komine M, Kishimoto M, et al. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016;43(11):1354–1357. doi: 10.1111/1346-8138.13515.
   PubMed Web of Science ®Google Scholar
• Kaul M, Jarvis P, Rozenberg I, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2021;35(5):1143–1151. doi: 10.1111/jdv.17071.
   PubMed Web of Science ®Google Scholar
• Khattri S, Goldblum O, Solotkin K, et al. Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis. J Clin Aesthet Dermatol. 2018;11:33–37.
   PubMedGoogle Scholar
• Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222–226. doi: 10.1038/nature14175.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124 e117. doi: 10.1016/j.jaci.2015.01.018.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Wharton KA, Jr., Schlitt T, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750–763. doi: 10.1016/j.jaci.2019.04.029.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258.
   PubMed Web of Science ®Google Scholar
• Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). Br J Dermatol. 2018;178(6):1315–1323. doi: 10.1111/bjd.16426.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. doi: 10.1111/bjd.15750.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266–276 e265. doi: 10.1016/j.jaad.2018.04.013.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/NEJMoa1503824.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349(21):2004–2013. doi: 10.1056/NEJMoa030002.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;69(3):385–392. doi: 10.1016/j.jaad.2013.03.031.
   PubMed Web of Science ®Google Scholar
• Lee JH, Youn JI, Kim TY, et al. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. BMC Dermatol. 2016;16(1):11. doi: 10.1186/s12895-016-0048-z.
   PubMedGoogle Scholar
• Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–436. doi: 10.1001/archdermatol.2010.384.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199. doi: 10.1056/NEJMoa1109997.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. doi: 10.1016/S0140-6736(08)60725-4.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 Pt 1):425–433. doi: 10.1016/j.jaad.2004.09.029.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022. doi: 10.1056/NEJMoa030409.
   PubMed Web of Science ®Google Scholar
• Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar (recombinant human tumor necrosis factor-alpha receptor II: igG Fc fusion protein) and methotrexate combination therapy in chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial. Arch Dermatol Res. 2020;312(6):437–445. doi: 10.1007/s00403-019-02024-6.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23(4):261–267. doi: 10.3109/09546634.2011.607795.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131. doi: 10.1136/annrheumdis-2019-215386.
   PubMed Web of Science ®Google Scholar
• Menter A, Arenberger P, Balser S, et al. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized phase III VOLTAIRE-PSO study. Expert Opin Biol Ther. 2021;21(1):87–96. doi: 10.1080/14712598.2021.1851362.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31 e31–15.
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141(1):31–38. doi: 10.1001/archderm.141.1.31.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115. doi: 10.1016/j.jaad.2007.09.010.
   PubMed Web of Science ®Google Scholar
• Micali G, Wilsmann-Theis D, Mallbris L, et al. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study. Acta Derm Venereol. 2015;95(1):57–61. doi: 10.2340/00015555-1845.
   PubMed Web of Science ®Google Scholar
• Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56(4):598–603. doi: 10.1016/j.jaad.2006.09.002.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36 e21. doi: 10.1016/j.jaad.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52. doi: 10.1016/j.jdermsci.2015.10.009.
   PubMed Web of Science ®Google Scholar
• Nemoto O, Hirose K, Shibata S, et al. Safety and efficacy of guselkumab in japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. Br J Dermatol. 2018;178(3):689–696. doi: 10.1111/bjd.16236.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–694. doi: 10.1111/1346-8138.14941.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Kubo H, Morishima H, et al. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062. doi: 10.1111/1346-8138.14504.
   PubMed Web of Science ®Google Scholar
• Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–663. doi: 10.1111/bjd.20827.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–1087. doi: 10.1111/bjd.12060.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–1102. doi: 10.1016/j.jaad.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–939. doi: 10.1111/bjd.13932.
   PubMed Web of Science ®Google Scholar
• Papp KA, Barber K, Bissonnette R, et al. A randomized, blinded assessor study to evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). J Eur Acad Dermatol Venereol. 2015;29(2):361–366. doi: 10.1111/jdv.12555.
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-Severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–1560. doi: 10.1056/NEJMoa1607017.
   PubMed Web of Science ®Google Scholar
• Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006;45(5):605–614. doi: 10.1111/j.1365-4632.2006.02777.x.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. doi: 10.1016/S0140-6736(08)60726-6.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421. doi: 10.1111/bjd.12110.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189. doi: 10.1056/NEJMoa1109017.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286 e210. doi: 10.1016/j.jaad.2018.03.037.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi: 10.1111/bjd.14493.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469. doi: 10.1038/jid.2012.163.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–1312. doi: 10.1111/j.1365-2133.2005.06688.x.
   PubMed Web of Science ®Google Scholar
• Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397(10284):1564–1575. doi: 10.1016/S0140-6736(21)00440-2.
   PubMed Web of Science ®Google Scholar
• Park KK, Wu JJ, Koo J. A randomized, ‘head-to-head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol. 2013;27(7):899–906. doi: 10.1111/j.1468-3083.2012.04611.x.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090. doi: 10.1111/jdv.12751.
   PubMed Web of Science ®Google Scholar
• Paul C, Puig L, Kragballe K, et al. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br J Dermatol. 2014;170(2):425–434. doi: 10.1111/bjd.12646.
   PubMed Web of Science ®Google Scholar
• Paul C, Stalder JF, Thaci D, et al. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2012;26(4):448–455. doi: 10.1111/j.1468-3083.2011.04093.x.
   PubMed Web of Science ®Google Scholar
• Pinter A, Hoffmann M, Reich K, et al. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). J Eur Acad Dermatol Venereol. 2021;35(3):701–711. doi: 10.1111/jdv.16932.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi: 10.1016/j.jaad.2016.11.042.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi: 10.1016/S0140-6736(19)31773-8.
   PubMed Web of Science ®Google Scholar
• Reich K, Augustin M, Thaci D, et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. 2020;182(4):869–879. doi: 10.1111/bjd.18384.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507–517. doi: 10.1111/jdv.14015.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. doi: 10.1016/S0140-6736(19)30952-3.
   PubMed Web of Science ®Google Scholar
• Reich K, Korber A, Mrowietz U, et al. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol. 2021;184(5):849–856. doi: 10.1111/bjd.19398.
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365(17):1586–1596. doi: 10.1056/NEJMoa1010858.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6.
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–190. doi: 10.1111/j.1365-2133.2012.10941.x.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi: 10.1016/S0140-6736(21)00125-2.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi: 10.1016/S0140-6736(17)31279-5.
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023. doi: 10.1111/bjd.15666.
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304–315. doi: 10.1111/bjd.18143.
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–966. doi: 10.1111/bjd.17351.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152. doi: 10.1056/NEJMoa2102383.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–411.
   PubMed Web of Science ®Google Scholar
• Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844–852. doi: 10.1111/bjd.16736.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Pietroleonardo L, Mazzotta A, et al. TNF-alpha antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther. 2013;13(4):469–473. doi: 10.1517/14712598.2013.736960.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566. doi: 10.1111/j.1365-2133.2007.08315.x.
   PubMed Web of Science ®Google Scholar
• Seo SJ, Shin BS, Lee JH, et al. Efficacy and safety of brodalumab in the korean population for the treatment of moderate to severe plaque psoriasis: a randomized, phase III, double-blind, placebo-controlled study. J Dermatol. 2021;48(6):807–817. doi: 10.1111/1346-8138.15733.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Schakel K, Hong CH, et al. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. J Dermatolog Treat. 2022;33(3):1718–1726. doi: 10.1080/09546634.2021.1902925.
   PubMed Web of Science ®Google Scholar
• Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040. doi: 10.1016/j.jaci.2014.01.025.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340(feb02 2):c147–c147. doi: 10.1136/bmj.c147.
   PubMedGoogle Scholar
• Sticherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024–1032. doi: 10.1111/bjd.15707.
   PubMed Web of Science ®Google Scholar
• Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661–668. doi: 10.1111/j.1365-2133.2011.10419.x.
   PubMed Web of Science ®Google Scholar
• Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24(3):169–178. doi: 10.3109/09546634.2012.658015.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi: 10.1016/j.jaad.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Thaci D, Eyerich K, Pinter A, et al. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naive patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2022;186(1):30–39. doi: 10.1111/bjd.20481.
   PubMed Web of Science ®Google Scholar
• Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777–787. doi: 10.1111/bjd.13814.
   PubMed Web of Science ®Google Scholar
• Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402–411. doi: 10.1111/j.1365-2133.2010.09791.x.
   PubMed Web of Science ®Google Scholar
• Thaci D, Pinter A, Sebastian M, et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2020;183(2):265–275. doi: 10.1111/bjd.18696.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H, Japanese Infliximab Study i. Infliximab monotherapy in japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40–49. doi: 10.1016/j.jdermsci.2010.04.014.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in taiwanese and korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–163. doi: 10.1016/j.jdermsci.2011.05.005.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35. doi: 10.1016/S0140-6736(05)67763-X.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Sakurai S, Hoshii N, et al. Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-Week results from a phase 2/3 japanese study. Dermatol Ther (Heidelb). 2021;11(2):513–528. doi: 10.1007/s13555-021-00494-z.
   PubMed Web of Science ®Google Scholar
• van Bezooijen JS, Balak DM, van Doorn MB, et al. Combination therapy of etanercept and fumarates versus etanercept monotherapy in psoriasis: a randomized exploratory study. Dermatology. 2016;232(4):407–414. doi: 10.1159/000448135.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159(5):1177–1185. doi: 10.1111/j.1365-2133.2008.08771.x.
   PubMed Web of Science ®Google Scholar
• Warren RB, Barker J, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-alpha inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2020;183(1):60–70. doi: 10.1111/bjd.18623.
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–141. doi: 10.1056/NEJMoa2102388.
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–59. doi: 10.1111/bjd.19341.
   PubMed Web of Science ®Google Scholar
• Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol. 2009;160(1):186–189. doi: 10.1111/j.1365-2133.2008.08926.x.
   PubMed Web of Science ®Google Scholar
• Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27(4):186–189. doi: 10.1111/j.1600-0781.2011.00594.x.
   PubMed Web of Science ®Google Scholar
• Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166(1):147–153. doi: 10.1111/j.1365-2133.2011.10616.x.
   PubMed Web of Science ®Google Scholar
• Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl). 2012;125(11):1845–1851.
   PubMed Web of Science ®Google Scholar
• Yu Q, Tong Y, Cui L, et al. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. Int Immunopharmacol. 2019;73:442–450. doi: 10.1016/j.intimp.2019.05.042.
   PubMed Web of Science ®Google Scholar
• Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495–501. doi: 10.2340/00015555-0511.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12:166–174.
   PubMed Web of Science ®Google Scholar
• Taichman DB, Backus J, Baethge C, et al. Sharing clinical trial data: a proposal from the international committee of medical journal editors. Lancet. 2016;387(10016):e9–e11. doi: 10.1016/S0140-6736(15)01279-9.
   PubMed Web of Science ®Google Scholar
• Yu K, Syed MN, Bernardis E, et al. Machine learning applications in the evaluation and management of psoriasis: a systematic review. J Psoriasis Psoriatic Arthritis. 2020;5(4):147–159. doi: 10.1177/2475530320950267.
   PubMedGoogle Scholar